286 related articles for article (PubMed ID: 28181832)
1. A tumor-targeting cRGD-EGFR siRNA conjugate and its anti-tumor effect on glioblastoma in vitro and in vivo.
He S; Cen B; Liao L; Wang Z; Qin Y; Wu Z; Liao W; Zhang Z; Ji A
Drug Deliv; 2017 Nov; 24(1):471-481. PubMed ID: 28181832
[TBL] [Abstract][Full Text] [Related]
2. Cytoplasmic expression of EGFR shRNA using a modified T7 autogene-based hybrid mRNA/DNA system induces long-term EGFR silencing and prolongs antitumor effects.
Seraj S; Cho YJ; Lee JW; Ahn HJ
Biochem Pharmacol; 2020 Jan; 171():113735. PubMed ID: 31786264
[TBL] [Abstract][Full Text] [Related]
3. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT
Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141
[TBL] [Abstract][Full Text] [Related]
4. Caged siRNAs with Single cRGD Modification for Photoregulation of Exogenous and Endogenous Gene Expression in Cells and Mice.
Yu L; Liang D; Chen C; Tang X
Biomacromolecules; 2018 Jul; 19(7):2526-2534. PubMed ID: 29727579
[TBL] [Abstract][Full Text] [Related]
5. Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA.
Liu X; Wang W; Samarsky D; Liu L; Xu Q; Zhang W; Zhu G; Wu P; Zuo X; Deng H; Zhang J; Wu Z; Chen X; Zhao L; Qiu Z; Zhang Z; Zeng Q; Yang W; Zhang B; Ji A
Nucleic Acids Res; 2014 Oct; 42(18):11805-17. PubMed ID: 25223783
[TBL] [Abstract][Full Text] [Related]
6. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
[TBL] [Abstract][Full Text] [Related]
7. Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma.
Michiue H; Eguchi A; Scadeng M; Dowdy SF
Cancer Biol Ther; 2009 Dec; 8(23):2306-13. PubMed ID: 19901546
[TBL] [Abstract][Full Text] [Related]
8.
Wan X; Sun R; Bao Y; Zhang C; Wu Y; Gong Y
Mol Pharm; 2021 Nov; 18(11):3990-3998. PubMed ID: 34591491
[TBL] [Abstract][Full Text] [Related]
9. RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model.
Lee TJ; Haque F; Shu D; Yoo JY; Li H; Yokel RA; Horbinski C; Kim TH; Kim SH; Kwon CH; Nakano I; Kaur B; Guo P; Croce CM
Oncotarget; 2015 Jun; 6(17):14766-76. PubMed ID: 25885522
[TBL] [Abstract][Full Text] [Related]
10. Systemic delivery of siRNA by T7 peptide modified core-shell nanoparticles for targeted therapy of breast cancer.
Yu MZ; Pang WH; Yang T; Wang JC; Wei L; Qiu C; Wu YF; Liu WZ; Wei W; Guo XY; Zhang Q
Eur J Pharm Sci; 2016 Sep; 92():39-48. PubMed ID: 27355138
[TBL] [Abstract][Full Text] [Related]
11. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma.
Costa PM; Cardoso AL; Custódia C; Cunha P; Pereira de Almeida L; Pedroso de Lima MC
J Control Release; 2015 Jun; 207():31-9. PubMed ID: 25861727
[TBL] [Abstract][Full Text] [Related]
12. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
Keir ST; Chandramohan V; Hemphill CD; Grandal MM; Melander MC; Pedersen MW; Horak ID; Kragh M; Desjardins A; Friedman HS; Bigner DD
J Neurooncol; 2018 Jul; 138(3):489-498. PubMed ID: 29564747
[TBL] [Abstract][Full Text] [Related]
13. pH-responsive hybrid quantum dots for targeting hypoxic tumor siRNA delivery.
Zhu H; Zhang S; Ling Y; Meng G; Yang Y; Zhang W
J Control Release; 2015 Dec; 220(Pt A):529-544. PubMed ID: 26590349
[TBL] [Abstract][Full Text] [Related]
14. Brain tumor-targeted therapy by systemic delivery of siRNA with Transferrin receptor-mediated core-shell nanoparticles.
Wei L; Guo XY; Yang T; Yu MZ; Chen DW; Wang JC
Int J Pharm; 2016 Aug; 510(1):394-405. PubMed ID: 27374198
[TBL] [Abstract][Full Text] [Related]
15. T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting.
Kuang Y; An S; Guo Y; Huang S; Shao K; Liu Y; Li J; Ma H; Jiang C
Int J Pharm; 2013 Sep; 454(1):11-20. PubMed ID: 23867728
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effect of STAT3‑targeted small interfering RNA and AZD0530 against glioblastoma in vitro and in vivo.
Liu Q; Wang L; Li D; Zhao J; Chen S; Li J
Mol Med Rep; 2019 Oct; 20(4):3625-3632. PubMed ID: 31485668
[TBL] [Abstract][Full Text] [Related]
17. Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects.
Song Z; Lin Y; Zhang X; Feng C; Lu Y; Gao Y; Dong C
Int J Nanomedicine; 2017; 12():1941-1958. PubMed ID: 28331317
[TBL] [Abstract][Full Text] [Related]
18. [Inhibitory effects of siRNA targeting epidermal growth factor receptor on proliferation and invasion of human glioblastoma cells].
Kang CS; Pu PY; Wang GX; Li YH; Dong L; Wang H
Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(18):1503-8. PubMed ID: 15500708
[TBL] [Abstract][Full Text] [Related]
19. [Effects of RNA interference on epidermal growth factor receptor expression in breast cancer cells: a study in tumor-bearing nude mice].
Wu WD; Fang CH; Yang ZX
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jan; 28(1):60-4. PubMed ID: 18227029
[TBL] [Abstract][Full Text] [Related]
20. Boosting RNAi therapy for orthotopic glioblastoma with nontoxic brain-targeting chimaeric polymersomes.
Shi Y; Jiang Y; Cao J; Yang W; Zhang J; Meng F; Zhong Z
J Control Release; 2018 Dec; 292():163-171. PubMed ID: 30408555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
